Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 2, 2019
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
December 20, 2018
iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a  global medical technology company providing innovative cancer detection and therapy solutions, today announced ...
December 20, 2018
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
December 20, 2018
Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD
SALT LAKE CITY, Dec. 20, 2018 /PRNewswire/ -- Lipocine Inc.(LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical ...
December 20, 2018
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
December 20, 2018
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
Transgene (TNG.PA), a biotechnology company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that the primary endpoint (safety and tolerability) was met ...
December 19, 2018
Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
CUPERTINO, Calif., Dec. 19, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that Indivior PLC (INDV.L) stated on December 18, 2018 that it is moving ahead with ...
December 19, 2018
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut ...
December 19, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
PALO ALTO, Calif., Dec. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...
December 19, 2018
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological ...
December 19, 2018
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
December 19, 2018
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the ...
December 19, 2018
Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
SAN DIEGO, Dec. 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will ...
December 19, 2018
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
JENA, Germany, Dec. 19, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the ...
December 19, 2018
Eyenovia Prices Public Offering of Common Stock
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of ...
December 19, 2018
MannKind Announces Commencement of Public Offering
WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue ...
December 19, 2018
Soleno Therapeutics Announces $16.5 Million Private Placement
REDWOOD CITY, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
December 19, 2018
Inspire Medical Systems, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative ...
December 19, 2018
FDA Approves New Indication for ENVARSUS XR® (tacrolimus extended-release tablets)
COPENHAGEN, Denmark, Dec. 19, 2018 /PRNewswire/ -- Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR ...
December 19, 2018
ADMA Biologics Provides Regulatory Update on BIVIGAM® PAS Submissions
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
Page 51 of 169